Listen to podcasts and conversations with key industry leaders
Their conversation provides insights and context to the OIS report from their unique perspectives as clinician-VCs. One insight shared by each was that the ophthalmic investment landscape is and will remain full of opportunities to meet growing unmet needs.
LensGen's Panel Discussion at ASCRS in Las Vegas Last August. Great news for LensGen, Inc. The approval of their IDE will allow the company to begin their pivotal trial with the ultimate goal of seeking premarket approval. Congratulations to Ram and the team! Their persistence and dedication is inspiring.
Learn
Our wide-ranging discussion touched on everything from the history and formation of ExSight, how we operate with two very busy vitreoretinal surgeons, our investment process, a pair of portfolio companies, and much more.
OIS Retina Podcast guest is French-born Patricia Zilliox, who boomeranged back to her homeland to become president and CEO of Eyevensys. Before that she’d spent 25 years with Alcon before joining the Foundation Fighting Blindness as chief drug development officer. Having spent so much time evaluating new therapies at FFB, she was intrigued by Eyevensys’ unique platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease. Listen to hear Patricia share more details on Eyevensys’ lead product: a gene therapy to treat uveitis.
In this third OIS Retina Podcast, host Firas Rahhal, MD, sat down with Paul Hallen, VP, Global Head, Retina, and Glaucoma, at Alcon, who talks about how he grew with the company over 31 years and provides an engineer’s perspective on how far innovation in retina surgery has come, and where it’s heading.
In this episode of the OIS Retina Podcast, Firas is joined by legendary vitreoretinal specialist and serial entrepreneur, Mark Blumenkranz, MD, MMS. It hasn’t always been smooth sailing in the start-up ship, but Dr. Blumenkranz persevered and now shares his proven recipe for ophthalmic innovation. (Hint: It starts with an unmet need.) Dr. Blumenkranz also talks about his investment/incubation firm Lagunitas Biosciencesio and drug delivery start-up Kedalion Therapeutics.
LensGen CEO Ram Rao sits down with Dr. Ehsan Sadri on the OIS Podcast to discuss his entrepreneurial journey, the recent financing, and the history of LensGen. Listen here and see below for a video of the discussion.
Trefoil Therapeutics begins first clinical trial of regenerative treatment for patients with corneal endothelial dystrophies.
Ophthalmology Innovation Summit TV Host: Firas M. Rahhal, MD, Partner – Exsight Ventures / Retina Vitreous Associates Medical Group speaks with Michael O'Rourke about ReVana's innovative photo cross-linking sustained drug delivery technology.
Financing Retinal Innovation panel at Ophthalmology Innovation Summit @ ASRS 2019
Sumit Garg, MD speaks for Omega Ophthalmics during the Post-Cataract Refractive Errors - Current Approaches and Unmet Needs segment at OIS@ASCRS 2019.
Sources of Capital Focusing on Ophthalmology Deals Panel at OIS@ASCRS 2019.